Archive
Explore Biotech & Programmable Life coverage by topic, keyword and publication date.
44 stories
Topics link related coverage, not verified causal connections.
Coherus Oncology is cutting 30% of its workforce as it narrows its clinical focus primarily onto esophageal cancer. The decision follows early-stage trial data showing strong anti-…
Read the brief →
AbCellera announced it will stop developing its experimental autoimmune drug ABCL575 after completing an early-stage trial. Although the drug met its primary safety goals, the comp…
Read the brief →
The U.S. Treasury's proposed rules to restrict outbound investments in China's biopharma sector have sparked intense concern among industry leaders and legal experts. While Washing…
Read the brief →
The U.S. Department of Health and Human Services announced up to $25 million in funding for ibogaine and other rapid-acting psychotropic drugs to treat serious mental illnesses lik…
Read the brief →
Cardiometabolic biotech Marea Therapeutics reports that its drug candidate MAR001 significantly reduced blood fat in a phase 2b study for patients with high triglycerides. The anti…
Read the brief →
Delix Therapeutics has secured $100 million in Series C funding to advance zalsupindole, a non-hallucinatory psychedelic therapy designed to treat major depressive disorder. Backed…
Read the brief →
Merck reports that its experimental drug efinopegdutide successfully treated MASH (metabolic dysfunction-associated steatohepatitis) in a mid-stage clinical trial. The drug outperf…
Read the brief →
Regeneron announced that its experimental monoclonal antibody, baloncibart, met its primary goal in a Phase 2 trial for postural orthostatic tachycardia syndrome, a chronic conditi…
Read the brief →
At the ObesityWeek 2026 conference, biopharma companies are shifting attention beyond standard GLP-1 drugs to explore new pathways like amylin modulation. Industry experts emphasiz…
Read the brief →
Smart ring maker Oura is acquiring telehealth startup Counsel Health, a platform previously promoted by drugmaker Eli Lilly for GLP-1 prescriptions. Experts warn this deal introduc…
Read the brief →
Researchers in genomics and proteomics often struggle with choosing the right statistical methods to avoid false discoveries. A recent Nature Biotechnology Comment proposes a 2 × 2…
Read the brief →
Zura Bio has discontinued development of its experimental drug tibulizumab for hidradenitis suppurativa after a phase 2 trial missed its primary endpoint. The trial failed because…
Read the brief →
Spruce Biosciences is spinning out its preclinical endocrinology program, including a monoclonal antibody for congenital adrenal hyperplasia, into a new entity called Adrenyx Biosc…
Read the brief →
Boehringer Ingelheim reports that its obesity drug survodutide has successfully met its primary endpoint in a late-stage cardiovascular safety trial, showing no increased risk of m…
Read the brief →
BioSpace reviews recent cardiovascular drug trials, noting that several late-stage failures have questioned traditional targets like IL-6 and lipoprotein(a). Despite these setbacks…
Read the brief →
Blackstone is backing Pfizer’s bet on a monthly obesity treatment. Meanwhile, the FDA commissioner nominee Heidi Overton is facing a tight Senate vote due to concerns over past vac…
Read the brief →
Addex Therapeutics spinout Neurosterix secured $105 million in a Series B financing round led by RTW Investments. The company plans to use the funds to advance its oral M4-targetin…
Read the brief →
Swiss biotech Windward is planning a Nasdaq IPO to raise over $200 million, primarily to fund respiratory drugs licensed from China. The company aims to advance its phase 2 and pha…
Read the brief →
Bristol Myers Squibb is combining its research and development into a single unit as the pharmaceutical giant faces impending patent expirations for its top-selling drugs. Chief Re…
Read the brief →
In a recent podcast episode, industry experts discuss why drug shortages are worsening. They explore how combining predictive analytics with flexible manufacturing could help make…
Read the brief →
Biogen is preparing to release the results of twin Phase 3 studies for its lupus drug, litifilimab, in early December. This upcoming data serves as a crucial test for the research…
Read the brief →
Columnist Adam Feuerstein re-evaluates his previous prediction about biotech company Alnylam reaching a $100 billion valuation. He notes that Alnylam must successfully address its…
Read the brief →
In a podcast conversation with Elad Gil, Isomorphic Labs president Max Jaderberg discusses the company's vision to shift drug discovery into a process of precision engineering thro…
Read the brief →
An FDA analysis of gene therapy applications from 1995 to 2025 shows rapid growth in adeno-associated virus development and identifies common reasons for regulatory holds, aiming t…
Read the brief →
A former Eli Lilly sales representative has filed a lawsuit claiming she was fired after reporting that the company unlawfully promoted its diabetes medication for weight loss befo…
Read the brief →
Broad kidney disease labels often hide important biological differences, which can mess up clinical trials. In a recent podcast, Dr. Ronen Schneider from Natera explains how geneti…
Read the brief →
PepGen's experimental drug for myotonic dystrophy type 1 achieved a record splicing correction of 46.5% in a mid-stage clinical trial, outperforming competitors and causing its sto…
Read the brief →
Capricor Therapeutics saw its operating expenses surge 70% in the third quarter as it ramps up manufacturing for its upcoming Duchenne muscular dystrophy cell therapy. With an FDA…
Read the brief →
According to Google DeepMind: Google has announced AlphaGenome 2, an AI model that predicts how DNA sequence variations impact specific human cell types and disease states. Trained…
Read the brief →
Faeth Therapeutics reported that its oral cancer therapy combination, called Piktor, hit key efficacy goals in a phase 2 trial for endometrial cancer. The drug achieved a 33% confi…
Read the brief →
Edesa Biotech has partnered with Kyorin Pharmaceutical to bring its late-stage respiratory drug to Japan in a deal worth up to $140 million. Kyorin will handle all local developmen…
Read the brief →
Scientific research rarely gives a simple first answer, and real progress often comes from looking beyond setbacks to find new questions. Ipsen's Chief Business Officer shares how…
Read the brief →
BioSpace is launching a weekly tracker to monitor the stock performance of U.S. biotechs that go public in 2026. After a long dry spell, biotech IPOs are finally making a comeback,…
Read the brief →
Novartis's gene therapy Zolgensma is under FDA investigation after nine patients developed tumors. Meanwhile, the FDA requires a safety warning for all GLP-1 weight loss drugs rega…
Read the brief →
According to MIT Biological Engineering: MIT's School of Engineering is welcoming new faculty across multiple disciplines, bringing fresh perspectives to research and teaching.
Read the brief →
The FDA's newly launched rare disease framework is facing its first major test as the agency decides whether to approve Capricor's cell therapy, deramiocel, for Duchenne muscular d…
Read the brief →
Beam Therapeutics announced that its CRISPR-based treatment for sickle cell disease successfully met the main goal in a key clinical trial. Patients achieved freedom from severe pa…
Read the brief →
Biotech company PepGen announced that its experimental drug showed promising early results in treating a severe muscle disorder affecting over 100,000 people. Although PepGen enter…
Read the brief →
According to MIT Biological Engineering: MIT researchers are leading a $53 million project funded by ARPA-H to create safer, next-generation weed killers. By using generative AI, t…
Read the brief →China's government has proposed blocking the sale of specific biotech platforms to foreign entities. This move adds key technologies in biomedicine, AI, and green energy to an expo…
Read the brief →The UK Biobank is teaming up with biotech companies to analyze blood samples from 80,000 people. They are building a massive immune dataset using AI and advanced tech, and separate…
Read the brief →Researchers have developed a statistical framework called RNA fingerprinting to match single-cell RNA sequencing data with reference perturbation dictionaries. Published in Cell, t…
Read the brief →
The FDA has approved Bayer's new drug, Sunharbo, to help prevent recurrent strokes. As the first in a novel class of medications, it targets a specific protein to block dangerous b…
Read the brief →
In this YC Paper Club discussion, experts explore how falling sequencing costs are transforming biology into a data-rich landscape. The speakers discuss cancer as a data problem an…
Read the brief →No matching stories yet. Clear filters or choose another field.